

BAMF Health Theranostics Center • Molecular Therapy Clinic 109 Michigan Street NW, Suite #200, Grand Rapids, MI 49503 Phone: (888) 870-8998 • Fax: (616) 253-8365 bamfhealth.com

Kisunla Order

Revision 01-17-2025

Please Fax completed order to BAMF Health at Fax # 616-253-8365	
PATIENT INFORMATION Referral Stat	us: New Referral Updated Order Order Renewal
Patient Name:	DOB:
Allergies:	Weight (kg): Height (cm):
REFERRING OFFICE (if applicable)	
Contact Name:	_ Contact Phone #:
Ordering Provider:	Provider NPI:
Practice Name:	Phone #: Fax #:
DIAGNOSIS Mild cognitive impairment, so stated (ICD-10 code: G31.84) Alzheimer's Disease with Early Onset (ICD-10 code: G30.0) Other:	 Alzheimer's Disease with Late Onset (ICD-10 code: G30.1) Mild dementia due to Alzheimer's Disease (ICD-10 code: G30.9) ICD-10 Code:
CLINICAL HISTORY – REQUIRED INFORMATION	
 Current Medication list Recent provider note(s) PET scan or CSF results with amyloid beta confirmation Recent MRI of brain (within past year) Results of cognitive assessment with score:	 Confirmation of functional impairment w/ validated tool: FAQ Score FAST CDR-SB For Medicare / Medicare Advantage, please include a copy of the CMS Registry enrollment that includes submission number APoE ε4 test results (if applicable)
PRE-MEDS	
Acetaminophen (Tylenol®) 650 mg PO prior to infusion	Decadron (dexamethasone) 10 mg IV Push over 5 min.
Please instruct patient to take acetaminophen 650 mg every 6 hours routinely for the next 24 hours while at home.	
NURSING ORDERS □ Vitals prior to infusion If SBP ≥ 150 mmHg, hold treatment and call provider. □ Vitals following infusion and prior to discharge Patients to be monitored for 30 min following completion of infusion Call prescriber and/or 911 for any hypersensitivity reactions including but not limited to fever, flu-like symptoms, nausea, vomiting, hypertension, and oxygen desaturation	
Date of last infusion if not at BAMF Health:	RX Expiration Date: (Rx will expire in 12 months)
THERAPY ADMINISTRATION	
Cycle 1: Kisunla 350mg/20mL. Administer 350mg in 50mL 0.9% NS IVPB over 30 minutes	
Cycle 2: Kisunla 350mg/20mL. Administer 700mg in 100mL 0.9% NS IVPB over 30 minutes	
Cycle 3: Kisunla 350mg/20mL. Administer 1050 mg in 200mL 0.9% NS IVPB over 30 minutes	
Cycles 4-18: Kisunla 350mg/20mL. Administer 1400 mg in 200mL 0.9% NS IVPB over 30 minutes	
Administer cycles 4 weeks apart	
FOLLOW UP MR BRAIN w/o contrast (Please use checkboxes below for al	lowing BAMF Health Nurse navigators to coordinate follow up MRIs at BAMF Health)
Rule Out: Amyloid related imaging abnormalities (Brain Ede	ma or Hemorrhage) 🗌 Other:
Order: MR Brain w/o contrast (prior to 2 nd Kisunla infusio	
MR Brain w/o contrast (prior to 3 rd Kisunla infusio	on) MR Brain w/o contrast (prior to 7 th Kisunla infusion)
Additional Orders: By signing this order, you agree to the following orders, unless otherwise noted.	
 Hold infusion and notify provider if patient reports: Headache, Dizziness, Nausea, Vision Changes, New or Worsening Confusion. May initiate IV catheter patency protocol Infusion/allergic reactions may be managed per facility protocol. 	
Provider Signature:	Date: